This indicates that the key N501Y mutation, which is found in the emerging U.K and South Africa variants, does not create resistance to the Pfizer-BioNTech vaccine induced immune responses.

Approved for Ages 12 and Up The Pfizer/BioNTech vaccine is currently approved for people 12 and older in South Africa. Pfizer is expecting trial data for children as young as 6 months “as soon ...

Introducing Life Uncensored; an interactive platform, specially created to provide a more human approach to medical conditions such as erectile dysfunction (ED), contraception and menopause (Pfizer ...

Pfizer said Friday that a clinical trial ... of the data looked at numbers from 1,219 adults in North and South America, Europe, Africa and Asia. Several companies are working on so-called oral ...

Data from a real-world study South Africa has indicated that the Omicron ... Top of the list is that while two doses of the Pfizer/BioNTech Comirnaty vaccine only seems to provide 33% protection ...

The Pfizer/BioNTech vaccine can still target a ... New variants have been detected in the UK and South Africa. Both forms of the virus are spreading more quickly and this has raised questions ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...